nct_id,phase,number_of_arms,brief_title,official_title,enrollment,a,b,comparator,combination
NCT00314574,Phase 3,2,A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA),"A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists",850,placebo,omalizumab,plac_stnd,FALSE
NCT01867125,Phase 3,3,A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication",1081,placebo,lebrikizumab,plac_stnd,FALSE
NCT02104674,Phase 3,3,A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA",313,placebo,lebrikizumab,plac_stnd,FALSE
NCT00831441,Phase 3,2,Phase III Acute Coronary Syndrome,"Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome",7484,placebo,apixaban,plac_stnd,FALSE
NCT00069784,Phase 3,4,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),"A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)",12537,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT00398931,Phase 3,NA,FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051),"A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial",1099,alendronate|placebo|duration statement,alendronate,undefined,NA
NCT01369329,Phase 3,3,A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1),"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)",769,placebo,ustekinumab,plac_stnd,FALSE
NCT01313676,Phase 3,4,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease,16568,NA,vilanterol,plac_stnd,FALSE
NCT01696110,Phase 4,3,BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.,Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT):a Randomised Controlled Trial,2194,NA,tirofiban,plac_stnd,FALSE
NCT01186146,Phase 4,2,Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE),Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events,5000,NA,clopidogrel,plac_stnd,FALSE
NCT00145925,Phase 3,2,Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes,ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation,11140,perindopril,gliclazide,diff_class,FALSE
NCT00259428,Phase 3,2,EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS),EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS),615,placebo,dronedarone,plac_stnd,FALSE
NCT00259376,Phase 3,2,American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm,American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS),629,placebo,dronedarone,plac_stnd,FALSE
NCT00970489,Phase 3,2,Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation,(OPERA)Randomized Clinical Trial to Examine Whether Peri-operative Intake of n-3 Polyunsaturated Fatty Acids Will Reduce the Occurrence of Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery,1516,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT01235130,Phase 3,2,Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation,"Phase 3 A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Long-chain N-3 Polyunsaturated Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation",337,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT00129545,Phase 2/Phase 3,3,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF),800,not a drug,warfarin,plac_stnd,FALSE
NCT00557921,Phase 3,2,Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1),"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease",5000,NA,omeprazole,plac_stnd,FALSE
NCT00141960,Phase 2/Phase 3,NA,Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease,"YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease",480,NA,famotidine,poss_plac_stnd,NA
NCT01009086,Phase 3,3,A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis",615,NA,ustekinumab,plac_stnd,FALSE
NCT01209702,Phase 3,5,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs,"A Ph II/III Seamless, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Reduction in Signs and Symptoms and Inhibition of Structural Damage During Treatment With Tocilizumab Versus Placebo in Patients With Ankylosing Spondylitis Who Have Failed Non-steroidal Anti-inflammatory Drugs and Are naïve to TNF Antagonist Therapy NSAIDs",306,placebo,tocilizumab,plac_stnd,FALSE
NCT01911364,Phase 3,3,Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease,A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease,3686,not a drug,tiotropium,plac_stnd,FALSE
NCT02579850,Phase 3,2,2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients,"52-week, Double Blind, Randomized, 2 Active Parallel Arms Study of Fixed Combination CHF 5993 Administered vs Ultibro® in COPD Patients",1532,NA,glycopyrronium bromide,plac_stnd,TRUE
NCT01009463,Phase 3,4,A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD),1626,NA,formoterol,plac_stnd,FALSE
NCT01017952,Phase 3,4,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD),1635,NA,formoterol,plac_stnd,FALSE
NCT00000479,Phase 3,4,Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer,Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women,39876,placebo,acetylsalicylic acid,plac_stnd,FALSE
NCT00312013,Phase 3,2,"Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer","A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate",503,standard care,nadroparin,plac_stnd,FALSE
NCT00694382,Phase 3,2,Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy,"A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy",3212,placebo,semuloparin,plac_stnd,FALSE
NCT00558259,Phase 3,2,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.,1353,placebo,dabigatran,plac_stnd,FALSE
NCT00740883,Phase 3,2,"Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. ""PADIS-PE"" Study.","Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Pulmonary Embolism: a Multicentre Double-blind Randomized Controlled Trial. ""PADIS-PE"" Study.",374,placebo,warfarin,plac_stnd,FALSE
NCT00977938,Phase 4,2,The Dual Antiplatelet Therapy Study (DAPT Study),"A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions",25682,placebo,prasugrel,plac_stnd,TRUE
NCT02064439,Phase 3,3,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism,3365,aminosalicylic acid,rivaroxaban,diff_class,FALSE
NCT00049829,Phase 3,NA,HORIZON-PFT: Pivotal Fracture Trial,HORIZON-PFT: Pivotal Fracture Trial,7700,NA,zoledronic acid,poss_plac_stnd,NA
NCT00046254,Phase 3,NA,Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture,NA,2127,NA,zoledronic acid,poss_plac_stnd,NA
NCT01343004,Phase 3,3,Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women,"A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture",2463,placebo,abaloparatide,plac_stnd,FALSE
NCT00089791,Phase 3,2,A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis,A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months),7808,placebo,denosumab,plac_stnd,FALSE
NCT01358175,Phase 3,3,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis",371,placebo,secukinumab,plac_stnd,FALSE
NCT01142726,Phase 3,3,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,"A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA",511,placebo,abatacept,plac_stnd,FALSE
NCT01087788,Phase 3,7,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,"Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)",409,NA,certolizumab pegol,plac_stnd,FALSE
NCT00111449,Phase 3,NA,Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis,A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis,600,NA,etanercept,poss_plac_stnd,NA
NCT01087762,Phase 3,7,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,"Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis",325,NA,certolizumab pegol,plac_stnd,FALSE
NCT01752634,Phase 3,4,"Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis",399,placebo,secukinumab,plac_stnd,FALSE
NCT00092703,Phase 3,NA,Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED),"A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis",6000,etoricoxib|etoricoxib,diclofenac,undefined,NA
NCT00092742,Phase 3,NA,Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072),"A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis",4086,etoricoxib|etoricoxib,diclofenac,undefined,NA
NCT00250445,Phase 3,NA,A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066),"A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis",23498,etoricoxib|etoricoxib,diclofenac,undefined,NA
NCT00032890,Phase 3,NA,Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT),Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT),1588,glucosamine|glucosamine|glucosamine,celecoxib,undefined,NA
NCT00422227,Phase 4,2,Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region,"A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis",300,sulfasalazine,leflunomide,diff_class,TRUE
NCT01451203,Phase 3,2,Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors",319,placebo,certolizumab pegol,plac_stnd,FALSE
NCT01208181,Phase 3,4,"A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK‑0663/Etoricoxib in Patients With Rheumatoid Arthritis",1404,NA,etoricoxib,plac_stnd,FALSE
NCT00106574,Phase 3,2,A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis,"A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy",1220,placebo,tocilizumab,plac_stnd,FALSE
NCT00565409,Phase 4,3,Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,"A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis",834,placebo,etanercept,plac_stnd,FALSE
NCT01721044,Phase 3,3,A Moderate to Severe Rheumatoid Arthritis Study,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors",527,placebo,baricitinib,plac_stnd,FALSE
NCT01523301,Phase 4,2,Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients,"Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients",380,placebo,rotigotine,plac_stnd,FALSE
NCT00542087,Phase 3,NA,Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED),"A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Etoricoxib 60 mg and Diclofenac Sodium 150 mg in Patient With Osteoarthritis of the Knee or Hip",516,etoricoxib|etoricoxib|duration statement,diclofenac,undefined,NA
NCT02000336,Phase 3,3,Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis,"Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial",386,placebo,prednisolone,plac_stnd,FALSE
NCT00299130,Phase 3,3,A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis,"A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis",511,placebo,rituximab,plac_stnd,TRUE
NCT01039688,Phase 3,3,"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","Phase 3 Randomized, Double-Blind Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Compared To Methotrexate In Methotrexate-Naive Patients With Rheumatoid Arthritis",968,antirheumatic,tofacitinib,diff_class,FALSE
NCT00077779,Phase 3,NA,Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease,"A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease",854,NA,adalimumab,poss_plac_stnd,NA
NCT00552058,Phase 3,2,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,"Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.",439,placebo,certolizumab pegol,plac_stnd,FALSE
NCT00264537,Phase 3,4,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,"A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis",637,NA,golimumab,plac_stnd,TRUE
NCT00327691,Phase 4,NA,A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels,"The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD",8600,NA,atorvastatin,poss_plac_stnd,NA
NCT01869491,Phase 3,2,Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study,"A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease",1107,placebo,sodium alginate,plac_stnd,FALSE
NCT00385736,Phase 3,3,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis,"A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis",576,placebo,adalimumab,plac_stnd,FALSE
NCT00783718,Phase 3,2,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis",895,placebo,vedolizumab,plac_stnd,FALSE
NCT00783692,Phase 3,2,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease",1116,placebo,vedolizumab,plac_stnd,FALSE
NCT00094458,Phase 3,3,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,"Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy",508,placebo,azathioprine,plac_stnd,FALSE
NCT01928771,Phase 3,3,Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma,"A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma",2681,placebo,benralizumab,plac_stnd,FALSE
NCT02149199,Phase 3,3,A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.,A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.,3850,NA,formoterol,plac_stnd,FALSE
NCT01285323,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,"A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma",464,placebo,reslizumab,plac_stnd,FALSE
NCT01706198,Phase 3,2,"An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma","A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma",4232,NA,vilanterol,plac_stnd,TRUE
NCT01475721,Phase 4,6,SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.,"SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma",11751,NA,salmeterol,plac_stnd,TRUE
NCT00148408,Phase 4,NA,Trial of Asthma Patient Education (TAPE),Trial of Asthma Patient Education (TAPE),600,NA,montelukast,poss_plac_stnd,NA
NCT00071331,Phase 3,NA,EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan,"Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure",3600,NA,tolvaptan,poss_plac_stnd,NA
NCT00125918,Phase 3,5,PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension,"PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension",406,placebo,tadalafil,plac_stnd,FALSE
NCT00325403,Phase 3,2,FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH),"A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension",349,placebo,treprostinil,plac_stnd,FALSE
NCT01106014,Phase 3,2,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,"A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension",1156,placebo,selexipag,plac_stnd,FALSE
NCT00303459,Phase 4,2,Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH),"Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study",334,placebo,bosentan,plac_stnd,FALSE
NCT00660179,Phase 3,3,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension",742,placebo,macitentan,plac_stnd,FALSE
NCT01178073,Phase 3,3,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),"AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)",610,NA,tadalafil,plac_stnd,FALSE
NCT00526474,Phase 3,2,Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)",26449,placebo,vorapaxar,plac_stnd,FALSE
NCT00268216,Phase 3,NA,Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD),"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment",6228,fluticasone,salmeterol,undefined,NA
NCT00144339,Phase 3,NA,Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).",5993,placebo,tiotropium,poss_plac_stnd,NA
NCT00563381,Phase 4,2,Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.,"Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).",7376,salmeterol,tiotropium,diff_class,FALSE
NCT01068600,Phase 3,2,Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease",318,placebo,indacaterol,plac_stnd,FALSE
NCT00846586,Phase 3,2,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,"A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease",1134,placebo,indacaterol,plac_stnd,FALSE
NCT00794157,Phase 3,3,Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A 12-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",347,placebo,indacaterol,plac_stnd,FALSE
NCT00297102,Phase 3,2,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124),Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study,1523,placebo,roflumilast,plac_stnd,FALSE
NCT00929110,Phase 3,3,"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)","A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease",1066,placebo,tiotropium,plac_stnd,FALSE
NCT00792805,Phase 3,3,Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD),"A Phase III, 26-week Multicenter Randomized Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",563,placebo,indacaterol,plac_stnd,FALSE
NCT01604278,Phase 3,2,"Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD",449,placebo,glycopyrronium bromide,plac_stnd,FALSE
NCT01110200,Phase 4,2,Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study,"A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization",639,NA,fluticasone,plac_stnd,TRUE
NCT01431274,Phase 3,5,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),"A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]",2624,NA,olodaterol,plac_stnd,FALSE
NCT01437397,Phase 3,5,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).",1692,NA,aclidinium bromide,plac_stnd,FALSE
NCT01782326,Phase 3,2,"QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)","A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).",3362,glycopyrronium bromide,indacaterol,diff_class,TRUE
NCT01697696,Phase 3,2,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,"A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation",511,R03AC Selective beta-2-adrenoreceptor agonists,glycopyrronium bromide,diff_class,TRUE
NCT01001494,Phase 3,3,Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients,Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),828,placebo,aclidinium bromide,plac_stnd,FALSE
NCT01964352,Phase 3,4,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),"A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",813,NA,olodaterol,plac_stnd,FALSE
NCT01914757,Phase 3,3,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,"A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)",2508,placebo,benralizumab,plac_stnd,FALSE
NCT01709903,Phase 3,2,"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD",744,NA,fluticasone,plac_stnd,FALSE
NCT00336336,Phase 3,4,GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF,A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure,6975,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT01985334,Phase 4,4,Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen,"A Prospective, Multicenter, 12-week, Randomized Open-label Study to Evaluate the Efficacy and Safety of Glycopyrronium (50 Micrograms o.d.) or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination (110/50 Micrograms o.d.) Regarding Symptoms and Health Status in Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD) Switching From Treatment With Any Standard COPD Regimen",4351,NA,indacaterol,plac_stnd,FALSE
NCT01854645,Phase 3,5,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control",2103,not a drug,tiotropium,plac_stnd,FALSE
NCT01715298,Phase 3,2,NVA237 BID Versus Placebo Twelve-week Efficacy Study,"A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients",432,placebo,glycopyrronium bromide,plac_stnd,FALSE
NCT01455129,Phase 4,2,Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China,"Early Intervention With Tiotropium （Spiriva） in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel, Multicentre Trial",841,placebo,tiotropium,plac_stnd,FALSE
NCT00393458,Phase 3,4,"Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control","A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control",1732,NA,indacaterol,plac_stnd,FALSE
NCT00652002,Phase 3,3,Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5,"A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5",450,NA,formoterol,plac_stnd,FALSE
NCT01443845,Phase 4,2,Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS),Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS),2354,placebo,roflumilast,plac_stnd,FALSE
NCT01908140,Phase 3,2,Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD),"A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)",933,salmeterol,aclidinium bromide,diff_class,TRUE
NCT00305162,Phase 3,2,A Clinical Trial to Demonstrate the Efficacy of Cangrelor,A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).,8882,NA,cangrelor,plac_stnd,FALSE
NCT00731692,Phase 3,3,"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.","A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis",970,placebo,fingolimod,plac_stnd,FALSE
NCT00740714,Phase 3,3,Effects of Coenzyme Q10 (CoQ) in Parkinson Disease,Effects of Coenzyme Q10 in Parkinson Disease - Phase III,600,placebo,coenzyme q10,plac_stnd,FALSE
NCT00099268,Phase 3,2,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,"A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy",747,NA,entacapone,plac_stnd,FALSE
NCT00256204,Phase 3,3,A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease,"A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects",1174,placebo,rasagiline,plac_stnd,FALSE
NCT00153062,Phase 4,4,PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes,"PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis",20332,NA,clopidogrel,plac_stnd,FALSE
NCT01225562,Phase 3,3,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin","A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction",21379,placebo,ticagrelor,plac_stnd,FALSE
NCT02465515,Phase 4,2,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus","A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus (HARMONY Outcomes)",9400,placebo,albiglutide,plac_stnd,FALSE
NCT00133692,Phase 4,NA,INVEST: INternational VErapamil SR Trandolapril STudy,INternational VErapamil SR Trandolapril STudy,22000,trandolapril|verapamil|atenolol,trandolapril,undefined,NA
NCT00338260,Phase 3,NA,Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133),"A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy",496,losartan|duration statement|duration statement,atenolol,undefined,NA
NCT00249873,Phase 3,2,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),"A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation",7554,placebo,clopidogrel,plac_stnd,FALSE
NCT00153036,Phase 3,NA,Rt-PA in the Treatment of Acute Ischemic Stroke,ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset,821,not a drug|placebo,B01AD Enzymes,undefined,NA
NCT00120289,Phase 3,2,Niacin Plus Statin to Prevent Vascular Events,AIM HIGH: Niacin Plus Statin to Prevent Vascular Events,3414,NA,niacin,plac_stnd,FALSE
NCT01131676,Phase 3,3,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,"A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk",7064,NA,empagliflozin,plac_stnd,FALSE
NCT00814268,Phase 4,2,COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke,"COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial",358,placebo,clopidogrel,plac_stnd,FALSE
NCT01252953,Phase 3,2,REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification,"REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease",30624,placebo,anacetrapib,plac_stnd,FALSE
NCT00562289,Phase 3,3,Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence,Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence,664,NA,rivaroxaban,plac_stnd,TRUE
NCT00202878,Phase 3,2,IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103),"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)",18144,NA,ezetimibe,plac_stnd,FALSE
NCT00091949,Phase 3,2,Insulin Resistance Intervention After Stroke Trial,Insulin Resistance Intervention After Stroke (IRIS) Trial,3876,placebo,pioglitazone,plac_stnd,FALSE
NCT01179048,Phase 3,2,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,"A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events",9340,placebo,liraglutide,plac_stnd,FALSE
NCT01032629,Phase 3,3,CANVAS - CANagliflozin cardioVascular Assessment Study,"A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus",4330,placebo,canagliflozin,plac_stnd,FALSE
NCT01776424,Phase 3,3,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).,27395,placebo,rivaroxaban,plac_stnd,FALSE
NCT00527943,Phase 3,2,Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)",12944,placebo,vorapaxar,plac_stnd,FALSE
NCT00077805,Phase 4,NA,PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin),"An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke",NA,NA,enoxaparin,poss_plac_stnd,NA
NCT00174993,Phase 3,2,Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes,PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy,4373,placebo,pioglitazone,plac_stnd,FALSE
NCT01720446,Phase 3,4,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,"A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)",3297,placebo,semaglutide,plac_stnd,FALSE
NCT00161070,Phase 4,NA,ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial,ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial,4500,acetylsalicylic acid|acetylsalicylic acid|anticoagulation,dipyridamole,undefined,NA
NCT00077753,Phase 4,NA,EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization,"A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization",4726,NA,enoxaparin,poss_plac_stnd,NA
NCT00221104,Phase 3,2,Japan Statin Treatment Against Recurrent Stroke (J-STARS),Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke,1578,standard care,pravastatin,plac_stnd,FALSE
NCT00120003,Phase 3,2,Scandinavian Candesartan Acute Stroke Trial (SCAST),Scandinavian Candesartan Acute Stroke Trial,2500,placebo,candesartan,plac_stnd,FALSE
NCT00073372,Phase 3,NA,A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II),"Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.",808,NA,abciximab,poss_plac_stnd,NA
NCT00053599,Phase 3,NA,Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease",400,NA,simvastatin,poss_plac_stnd,NA
NCT02017340,Phase 3,2,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease,511,placebo,nilvadipine,plac_stnd,FALSE
NCT00216593,Phase 3,NA,Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study,"Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.",415,NA,galantamine,poss_plac_stnd,NA
NCT00792636,Phase 4,3,"A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period","Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults",407,NA,naproxen,plac_stnd,FALSE
NCT00000609,Phase 3,NA,Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT),NA,NA,NA,amiodarone,poss_plac_stnd,NA
NCT00000620,Phase 3,6,Action to Control Cardiovascular Risk in Diabetes (ACCORD),Action to Control Cardiovascular Risk in Diabetes (ACCORD),10251,not a drug,fenofibric acid,plac_stnd,TRUE
NCT00105027,Phase 3,6,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema,682,standard care,triamcinolone,plac_stnd,FALSE
NCT00649389,Phase 3,4,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,"A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension",2500,NA,olmesartan,plac_stnd,FALSE
NCT01644175,Phase 3,2,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",316,placebo,alirocumab,plac_stnd,FALSE
NCT02145468,Phase 3,2,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.,3503,placebo,losmapimod,plac_stnd,FALSE
NCT01897532,Phase 4,2,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),"CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk",7003,placebo,linagliptin,plac_stnd,FALSE
NCT02738632,Phase 3,2,Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients,"Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination",300,placebo,hydrochlorothiazide,plac_stnd,FALSE
NCT00093158,Phase 3,NA,Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS),The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation,13800,NA,bivalirudin,poss_plac_stnd,NA
NCT02585778,Phase 3,2,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy",517,placebo,alirocumab,plac_stnd,FALSE
NCT00430677,Phase 2/Phase 3,4,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,"A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)",423,NA,prednisolone,plac_stnd,TRUE
NCT00081731,Phase 3,2,Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions,Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL),947,NA,candesartan,plac_stnd,TRUE
NCT00308347,Phase 3,NA,A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED),"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy",1513,losartan|placebo|duration statement,losartan,undefined,NA
NCT00211705,Phase 4,NA,Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study),Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study),8000,lifestyle,pravastatin,undefined,NA
NCT00614939,Phase 3,2,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,"A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin Compared With Placebo in Adult Patients With Type 2 Diabetes and Renal Impairment (Moderate, Severe, and End-Stage) With an Additional 40-week, Randomized, Double-blind, Placebo-controlled Long-term Observational Period.",572,placebo,saxagliptin,plac_stnd,FALSE
NCT00863707,Phase 4,2,A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment,"A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment",511,placebo,regadenoson,plac_stnd,FALSE
NCT00633893,Phase 3,3,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism,2711,placebo,apixaban,plac_stnd,FALSE
NCT00968708,Phase 3,2,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome",5380,placebo,alogliptin,plac_stnd,FALSE
NCT00663260,Phase 2/Phase 3,3,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control",631,placebo,dapagliflozin,plac_stnd,FALSE
NCT01185938,Phase 4,2,Statin Contrast Induced Nephropathy Prevention,Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial,500,standard care,rosuvastatin,plac_stnd,FALSE
NCT00790205,Phase 3,2,Sitagliptin Cardiovascular Outcomes Study (MK-0431-082),"TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control",14671,placebo,sitagliptin,plac_stnd,FALSE
NCT01623115,Phase 3,2,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",486,placebo,alirocumab,plac_stnd,FALSE
NCT01107886,Phase 4,2,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,"A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes",18206,placebo,saxagliptin,plac_stnd,FALSE
NCT01926782,Phase 3,3,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia",803,NA,alirocumab,plac_stnd,FALSE
NCT01986855,Phase 3,3,A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy",468,NA,ertugliflozin,plac_stnd,FALSE
NCT01813435,Phase 3,2,GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation,Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-day Intensive Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention With Bivalirudin and BioMatrix Family Drug-eluting Stent Use,16000,NA,clopidogrel,plac_stnd,FALSE
NCT00475852,Phase 3,2,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,"Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)",7141,placebo,nesiritide,plac_stnd,FALSE
NCT00185159,Phase 3,2,Olmesartan Medoxomil in Diabetes Mellitus,Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP),4449,placebo,olmesartan,plac_stnd,FALSE
NCT00174915,Phase 3,5,"Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.","A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.",1072,placebo,allopurinol,plac_stnd,FALSE
NCT00818883,Phase 3,2,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,"A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension",609,hydrochlorothiazide,chlorthalidone,diff_class,FALSE
NCT00269906,Phase 3,2,"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty",Chimeric Anti-Platelet Therapy (Abciximab) in Unstable Angina Refractory to Standard Medical Therapy Trial (CAPTURE),1265,placebo,abciximab,plac_stnd,FALSE
NCT00170924,Phase 4,NA,"To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.","A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction",317,NA,valsartan,poss_plac_stnd,NA
NCT00439725,Phase 3,2,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study,1197,placebo,rivaroxaban,plac_stnd,FALSE
NCT00954447,Phase 3,2,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy",1263,placebo,linagliptin,plac_stnd,FALSE
NCT01164501,Phase 3,3,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control",741,NA,empagliflozin,plac_stnd,FALSE
NCT01438814,Phase 4,2,Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control,"A Randomised, Double-blind, Double-dummy, Active-comparator Controlled Study Investigating the Efficacy and Safety of Linagliptin Co-administered With Metformin QD at Evening Time Versus Metformin BID Over 14 Weeks in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control",689,placebo,linagliptin,plac_stnd,FALSE
NCT01836523,Phase 3,6,The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes,"The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial",1398,placebo,liraglutide,plac_stnd,FALSE
NCT01510158,Phase 3,3,Combining Lesinurad With Allopurinol in Inadequate Responders,"A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol.",607,placebo,lesinurad,plac_stnd,FALSE
NCT01493531,Phase 3,3,Combining Lesinurad With Allopurinol in Inadequate Responders,"A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol",610,placebo,lesinurad,plac_stnd,FALSE
NCT00829660,Phase 4,2,Acarbose Cardiovascular Evaluation Trial,"A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance",6526,placebo,acarbose,plac_stnd,FALSE
NCT00206310,Phase 3,NA,Crestor Versus Placebo in Subjects With Heart Failure,"Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure",5013,NA,rosuvastatin,poss_plac_stnd,NA
NCT01368081,Phase 3,3,Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus,"A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control",1162,placebo,empagliflozin,plac_stnd,TRUE
NCT00454896,Phase 3,2,A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB),"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder",739,placebo,solifenacin,plac_stnd,FALSE
NCT00927394,Phase 4,2,Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus,"An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus",1143,NA,aliskiren,plac_stnd,FALSE
NCT00555217,Phase 3,2,VA NEPHRON-D: Diabetes iN Nephropathy Study,CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study),1448,NA,lisinopril,plac_stnd,FALSE
NCT01327846,Phase 3,4,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),"A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP",10067,placebo,canakinumab,plac_stnd,FALSE
NCT01621178,Phase 3,3,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease",577,insulin glargine,dulaglutide,diff_class,FALSE
NCT01147250,Phase 3,2,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome",6068,placebo,lixisenatide,plac_stnd,FALSE
NCT01792518,Phase 3,2,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)",360,placebo,linagliptin,plac_stnd,FALSE
NCT01395745,Phase 3,2,CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus",442,placebo,blisibimod,plac_stnd,FALSE
NCT00384930,Phase 2/Phase 3,5,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",1058,placebo,tadalafil,plac_stnd,FALSE
NCT00827242,Phase 3,2,Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",325,placebo,tadalafil,plac_stnd,FALSE
NCT00855582,Phase 3,3,A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men With Both Erectile Dysfunction and Benign Prostatic Hyperplasia",606,placebo,tadalafil,plac_stnd,FALSE
NCT02390882,Phase 3,3,A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH,"A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia",494,placebo,tamsulosin,plac_stnd,FALSE
NCT01321255,Phase 3,2,Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.,Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug,2118,NA,ramipril,plac_stnd,TRUE
NCT01543555,Phase 3,2,Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose,Multicenter Randomized Controlled Trial of Loading Dose Statins for the Prevention of Cardiovascular Complications in High-Risk Non-Cardiac Surgery,648,placebo,atorvastatin,plac_stnd,FALSE
NCT00097786,Phase 3,4,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,"A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)",9306,placebo,nateglinide,plac_stnd,FALSE
NCT00602472,Phase 3,2,BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes,"A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea",1058,placebo,linagliptin,plac_stnd,FALSE
NCT00327015,Phase 3,4,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control",1306,placebo,saxagliptin,plac_stnd,FALSE
NCT00000542,Phase 3,NA,Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),NA,NA,lisinopril|pravastatin|chlorthalidone,doxazosin,undefined,NA
NCT01081834,Phase 3,3,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise",678,placebo,canagliflozin,plac_stnd,TRUE
NCT01144338,Phase 3,2,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.",14752,placebo,exenatide,plac_stnd,FALSE
NCT01730534,Phase 3,2,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes",17276,placebo,dapagliflozin,plac_stnd,FALSE
NCT00134160,Phase 4,2,OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study,The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk,1000,olmesartan,azelnidipine,diff_class,TRUE
NCT00397657,Phase 4,2,Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis,ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS),400,NA,niacin,plac_stnd,FALSE
NCT00433966,Phase 3,2,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™),3602,bivalirudin,paclitaxel,diff_class,TRUE
NCT00174785,Phase 3,2,A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation,"A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)",4628,placebo,dronedarone,plac_stnd,FALSE
NCT01813422,Phase 3,2,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,"A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization",970,placebo,evolocumab,plac_stnd,FALSE
NCT01502774,Phase 3,2,Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients,Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients,970,placebo,ciclosporin,plac_stnd,FALSE
NCT00000556,Phase 3,NA,Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM),NA,NA,antagon|procainamide|disopyramide,verapamil,undefined,NA
NCT00376272,Phase 3,2,GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence,"Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence",1442,placebo,valsartan,plac_stnd,FALSE
NCT01176968,Phase 4,2,Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction,"A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction",1012,placebo,eplerenone,plac_stnd,FALSE
NCT00417222,Phase 3,2,Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan,Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial),1145,standard care,olmesartan,plac_stnd,FALSE
NCT00095238,Phase 3,2,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),4128,placebo,irbesartan,plac_stnd,FALSE
NCT00046228,Phase 3,3,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),"A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.",2461,NA,reteplase,plac_stnd,FALSE
NCT02441218,Phase 3,2,Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study,NA,6505,placebo,ivabradine,plac_stnd,FALSE
NCT01130246,Phase 3,2,VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome,VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes,5189,placebo,varespladib,plac_stnd,TRUE
NCT00094302,Phase 3,2,Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function,Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT),3445,placebo,spironolactone,plac_stnd,FALSE
NCT00099788,Phase 3,2,Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes,"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes",6560,placebo,ranolazine,plac_stnd,FALSE
NCT01035255,Phase 3,2,This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure,"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction",8442,valsartan and sacubitril,enalapril,diff_class,TRUE
NCT01661634,Phase 3,2,Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure,"Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]",2157,placebo,ularitide,plac_stnd,FALSE
NCT01930682,Phase 4,2,EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction,"EARLY Routine Catheterization or Rescue Angioplasty After Alteplase Fibrinolysis vs. Primary Angioplasty in Acute ST-elevation MYOcardial Infarction: An Open, Prospective, Randomized, Multicentre Trial",344,NA,alteplase,plac_stnd,FALSE
NCT00000476,Phase 3,NA,Digitalis Investigation Group (DIG),NA,NA,NA,digoxin,poss_plac_stnd,NA
NCT00139386,Phase 4,2,Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial,Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation,1119,standard care,candesartan,plac_stnd,FALSE
NCT00043784,Phase 3,NA,SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes,"A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)",8000,NA,enoxaparin,poss_plac_stnd,NA
NCT00133003,Phase 4,2,"Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)","Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)",2022,placebo,abciximab,plac_stnd,FALSE
NCT00251576,Phase 3,NA,Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180),"A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction With Aspirin",4497,heparin|heparin|heparin,tirofiban,undefined,NA
NCT00827411,Phase 4,4,"Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy","Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting",2500,NA,prasugrel,plac_stnd,TRUE
NCT01291641,Phase 4,3,Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy,"Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study",342,NA,probucol,plac_stnd,FALSE
NCT02446990,Phase 3,2,Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure,Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease,19102,placebo,ivabradine,plac_stnd,FALSE
NCT00986050,Phase 4,4,Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction,A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study,907,not a drug,sirolimus,plac_stnd,FALSE
NCT00432796,Phase 3,2,PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.,A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2),1473,placebo,dalteparin,plac_stnd,FALSE
NCT00092651,Phase 3,NA,A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, ""Factorial"" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia",1398,simvastatin|ezetimibe|ezetimibe,simvastatin,undefined,NA
NCT00231738,Phase 4,NA,Protective Effect of EPA on Cardiovascular Events,Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS),18000,NA,omega-3-triglycerides incl. other esters and acids,poss_plac_stnd,NA
NCT00947843,Phase 4,3,Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents,"Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial",306,placebo,clopidogrel,plac_stnd,FALSE
NCT00092690,Phase 3,NA,MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED),"A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia",1902,ezetimibe|ezetimibe|atorvastatin,simvastatin,undefined,NA
NCT01763866,Phase 3,24,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,"A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia",2067,placebo,evolocumab,plac_stnd,FALSE
NCT00269893,Phase 3,3,"A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty","A Phase III Double-Blind, Placebo-Controlled Multicenter Study of Abciximab In Patients Undergoing High Risk Coronary Angioplasty (EPIC)",2038,NA,abciximab,plac_stnd,FALSE
NCT00283335,Phase 3,2,The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol,CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol,2531,placebo,gemfibrozil,plac_stnd,FALSE
NCT00133250,Phase 4,2,Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3),Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3),800,placebo,abciximab,plac_stnd,FALSE
NCT00077792,Phase 3,NA,Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25),"A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy",20506,NA,enoxaparin,poss_plac_stnd,NA
NCT00623623,Phase 3,2,STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction,STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms,1891,NA,tenecteplase,plac_stnd,TRUE
NCT02777580,Phase 4,2,STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction,STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction,600,NA,tenecteplase,plac_stnd,TRUE
NCT01347580,Phase 4,2,A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI),"A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.",1875,placebo,ticagrelor,plac_stnd,FALSE
NCT01573143,Phase 4,2,Statin Therapy In Cardiac Surgery,Statin Therapy In Cardiac Surgery,1922,placebo,rosuvastatin,plac_stnd,FALSE
NCT00222573,Phase 4,NA,Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction,Clopidogrel Or Metoprolol in Myocardial Infarction Trial,46000,clopidogrel,metoprolol,undefined,NA
NCT01059136,Phase 3,2,Aldosterone Blockade Early After Acute Myocardial Infarction,Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL,1603,standard care,spironolactone,plac_stnd,FALSE
NCT00168792,Phase 4,NA,A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI),"A Phase IIIb - IV, Randomised, Open Label Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early PCI as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction. ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.)",1671,NA,tenecteplase,poss_plac_stnd,NA
NCT00000558,Phase 3,NA,Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE),NA,NA,NA,angiotensin-converting enzyme inhibitors,poss_plac_stnd,NA
NCT01663402,Phase 3,2,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome",18600,placebo,alirocumab,plac_stnd,FALSE
NCT01287117,Phase 3,4,A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",319,placebo,omalizumab,plac_stnd,FALSE
NCT02666664,Phase 3,2,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony),"A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy",2233,placebo,bempedoic acid,plac_stnd,FALSE
NCT00783263,Phase 3,4,A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139),"A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease",440,NA,ezetimibe,plac_stnd,FALSE
NCT00418834,Phase 3,2,Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112),"A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHD",1053,NA,ezetimibe,plac_stnd,FALSE
NCT00000614,Phase 3,NA,Prevention of Recurrent Venous Thromboembolism (PREVENT),NA,NA,NA,warfarin,poss_plac_stnd,NA
NCT00089895,Phase 3,2,EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED),"Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)",9406,placebo,eptifibatide,plac_stnd,FALSE
NCT00090168,Phase 3,NA,Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED),A Multicenter Study to Assess the Cholesterol Lowering Level of Switching to an Investigational Drug Compared to Doubling the Dose of an Investigational Drug in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease,435,ezetimibe|ezetimibe|atorvastatin,simvastatin,undefined,NA
NCT00327145,Phase 3,NA,A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy,"A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy",894,hydrochlorothiazide|amlodipine,valsartan,undefined,NA
NCT00092625,Phase 3,NA,Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.",442,ezetimibe|ezetimibe|placebo,ezetimibe,undefined,NA
NCT00350168,Phase 3,NA,Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension,An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension,647,amlodipine,valsartan,undefined,NA
NCT00441350,Phase 3,2,Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension,Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension,1004,NA,hydrochlorothiazide,plac_stnd,FALSE
NCT00541697,Phase 3,NA,Eze/Simva Switch Study in Diabetics (0653A-807),"A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes.",648,ezetimibe|ezetimibe|atorvastatin,simvastatin,undefined,NA
NCT00280540,Phase 4,NA,Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension,"A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension",648,hydrochlorothiazide,valsartan,undefined,NA
NCT00225589,Phase 3,NA,A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR),"A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)",840,NA,rosuvastatin,poss_plac_stnd,NA
NCT02414854,Phase 3,4,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma",1902,placebo,dupilumab,plac_stnd,FALSE
NCT01508936,Phase 3,2,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,"A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma",511,placebo,reslizumab,plac_stnd,FALSE
NCT02105948,Phase 3,2,Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients,Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients,837,placebo,mepolizumab,plac_stnd,FALSE
NCT01691521,Phase 3,3,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,"MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma",580,NA,mepolizumab,plac_stnd,FALSE
NCT01484496,Phase 3,2,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)",839,placebo,belimumab,plac_stnd,FALSE
NCT01597245,Phase 3,5,A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis",1224,placebo,ixekizumab,plac_stnd,FALSE
NCT00106847,Phase 3,NA,A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance InfliximabTherapy in Patients With Plaque-Type Psoriasis",683,NA,infliximab,poss_plac_stnd,NA
NCT00237887,Phase 3,NA,Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis,"A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis",1212,NA,adalimumab,poss_plac_stnd,NA
NCT01358578,Phase 3,6,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis","A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",1306,NA,secukinumab,plac_stnd,FALSE
NCT01695239,Phase 3,4,A Study of Ixekizumab in Participants With Active Psoriatic Arthritis,"A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis",417,placebo,ixekizumab,plac_stnd,FALSE
NCT00092586,Phase 3,NA,Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040),"A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level",2904,ezetimibe|C10AA HMG CoA reductase inhibitors,ezetimibe,undefined,NA
NCT00154271,Phase 4,NA,Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP),Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP),1677,valsartan,valsartan,undefined,NA
NCT00300456,Phase 3,6,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,"A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia",657,placebo,choline fenofibrate,plac_stnd,FALSE
NCT00276484,Phase 3,2,To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090),"A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at High Risk for CHD Not Adequately Controlled on Atorvastatin 40 Mg",579,NA,ezetimibe,plac_stnd,FALSE
NCT00463606,Phase 3,3,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,"A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia",760,NA,choline fenofibrate,plac_stnd,FALSE
NCT00251134,Phase 3,2,OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction,"OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.",3800,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT00300482,Phase 3,6,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,"A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia",1445,placebo,choline fenofibrate,plac_stnd,FALSE
NCT00822211,Phase 3,3,Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy",404,placebo,vildagliptin,plac_stnd,FALSE
NCT00035984,Phase 3,4,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus,"A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea",734,placebo,exenatide,plac_stnd,FALSE
NCT00407537,Phase 4,1,Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors,A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice,1531,standard care,atorvastatin,plac_stnd,TRUE
NCT00059306,Phase 3,2,Secondary Prevention of Small Subcortical Strokes Trial,Secondary Prevention of Small Subcortical Strokes (SPS3) Trial,3020,not a drug,clopidogrel,plac_stnd,TRUE
NCT00131846,Phase 4,2,Diuretics In the Management of Essential Hypertension (DIME) Study,Effect of Low Dose Thiazide Diuretics on New Onset Type 2 Diabetes in Patients With Essential Hypertension,1130,thiazide diuretic,diuretics,diff_class,FALSE
NCT00685776,Phase 3,2,Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019),"A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease",1623,placebo,anacetrapib,plac_stnd,FALSE
NCT00853827,Phase 3,2,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,"A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy",613,placebo,aliskiren,plac_stnd,FALSE
NCT00121641,Phase 3,5,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise",1035,NA,saxagliptin,plac_stnd,FALSE
NCT00713830,Phase 3,2,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea",859,placebo,lixisenatide,plac_stnd,FALSE
NCT01516879,Phase 3,2,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,"A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects",905,placebo,evolocumab,plac_stnd,FALSE
NCT00596752,Phase 4,2,Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV,"Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)",840,placebo,alprostadil,plac_stnd,FALSE
NCT02058160,Phase 3,2,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,"A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)",736,NA,lixisenatide,plac_stnd,FALSE
NCT02058147,Phase 3,3,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,"A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)",1170,NA,lixisenatide,plac_stnd,FALSE
NCT00853658,Phase 3,3,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,"A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).",7064,NA,enalapril,plac_stnd,FALSE
NCT01272219,Phase 3,5,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,"Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation",3731,placebo,liraglutide,plac_stnd,FALSE
NCT00135226,Phase 4,4,ASCEND: A Study of Cardiovascular Events iN Diabetes,"A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes",15480,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT01507831,Phase 3,2,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),"Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study",2341,placebo,alirocumab,plac_stnd,FALSE
NCT01492361,Phase 3,2,A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.,Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial),8000,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT02630706,Phase 3,3,A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy",506,NA,ertugliflozin,plac_stnd,FALSE
NCT00733902,Phase 3,4,Tanezumab in Osteoarthritis of the Knee,"A Phase 3 Randomized, Double Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee",697,placebo,tanezumab,plac_stnd,FALSE
NCT00170950,Phase 3,2,Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension,"A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension",11506,amlodipine,hydrochlorothiazide,diff_class,FALSE
NCT00086502,Phase 3,2,Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy",353,placebo,sitagliptin,plac_stnd,FALSE
NCT00121667,Phase 3,4,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,"""A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone""",1462,placebo,saxagliptin,plac_stnd,FALSE
NCT00313313,Phase 3,3,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone",768,placebo,saxagliptin,plac_stnd,FALSE
NCT00395343,Phase 3,2,Sitagliptin Added-on to Insulin Study (0431-051),"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)",641,placebo,sitagliptin,plac_stnd,FALSE
NCT00397631,Phase 3,2,Initial Combination With Pioglitazone Study (0431-064),"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus",520,placebo,sitagliptin,plac_stnd,FALSE
NCT00482729,Phase 3,2,MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED),"A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)",1246,NA,sitagliptin,plac_stnd,FALSE
NCT00328627,Phase 3,12,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes",1554,placebo,alogliptin,plac_stnd,FALSE
NCT01524289,Phase 3,2,Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020),"A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia",306,placebo,anacetrapib,plac_stnd,FALSE
NCT02203916,Phase 3,3,Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension",328,placebo,azilsartan,plac_stnd,FALSE
NCT01191268,Phase 3,3,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4),884,insulin glargine,dulaglutide,diff_class,FALSE
NCT01154036,Phase 3,8,MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162),"A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin",1547,NA,ezetimibe,plac_stnd,FALSE
NCT01717300,Phase 3,3,A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021),"A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C",459,NA,anacetrapib,plac_stnd,FALSE
NCT00220961,Phase 3,2,Actos Now for Prevention of Diabetes (ACT NOW),Actos Now for Prevention of Diabetes (ACT NOW),602,placebo,pioglitazone,plac_stnd,FALSE
NCT00289848,Phase 3,2,MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",530,placebo,sitagliptin,plac_stnd,FALSE
NCT00094757,Phase 3,3,An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023),"A Multicenter, Randomized, Double-Blind Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",521,sitagliptin,pioglitazone,plac_stnd,TRUE
NCT00295633,Phase 3,3,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,"A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone",565,placebo,saxagliptin,plac_stnd,FALSE
NCT00853957,Phase 4,2,Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension,"An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension",443,NA,aliskiren,plac_stnd,FALSE
NCT00093899,Phase 3,NA,A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED),A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia,611,ezetimibe,simvastatin,undefined,NA
NCT00038961,Phase 3,2,A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).,"A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdomi",1309,placebo,fondaparinux,plac_stnd,FALSE
NCT00237237,Phase 3,NA,Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes,Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes,588,NA,vildagliptin,poss_plac_stnd,NA
NCT01257451,Phase 3,2,Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents)",431,placebo,vildagliptin,plac_stnd,FALSE
NCT00714961,Phase 3,2,Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction,"A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy",3491,placebo,clopidogrel,plac_stnd,FALSE
NCT00227318,Phase 3,NA,TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)",1000,NA,candesartan,poss_plac_stnd,NA
NCT00279045,Phase 3,NA,Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide,"A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus",4426,metformin|glibenclamide,rosiglitazone,undefined,NA
NCT00101751,Phase 4,NA,INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study,"Efficacy and Safety of a Standard Titration Algorithm Coupled With a Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Algorithm, Alone, in Patients With Type 2 Diabetes Initiating NovoLog® Mix 70/30 Therapy",4877,NA,insulin aspart,poss_plac_stnd,NA
NCT01885208,Phase 3,2,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1),813,exenatide,semaglutide,same_5,FALSE
NCT01930188,Phase 3,4,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor),1231,sitagliptin,semaglutide,same_4,FALSE
NCT02054897,Phase 3,4,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,388,placebo,semaglutide,plac_stnd,FALSE
NCT02207374,Phase 3,3,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes,Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy,601,dpp-4 inhibitor,semaglutide,same_4,FALSE
NCT02128932,Phase 3,3,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,1089,insulin glargine,semaglutide,diff_class,FALSE
NCT02305381,Phase 3,4,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,397,placebo,semaglutide,plac_stnd,FALSE
NCT02706847,Phase 3,4,A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs,"A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)",499,placebo,upadacitinib tartrate,plac_stnd,TRUE
NCT00734630,Phase 4,2,Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension.",491,placebo,nebivolol,plac_stnd,FALSE
NCT00791999,Phase 2/Phase 3,4,Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA),"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX.",316,placebo,certolizumab pegol,plac_stnd,FALSE
NCT00627016,Phase 3,2,A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn,"A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)",305,placebo,dexlansoprazole,plac_stnd,FALSE
NCT00359905,Phase 3,3,Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH,"Evaluation of the Efficacy and Safety of Silodosin vs. Tamsulosin and Placebo in the Treatment of the Signs and Symptoms of BPH. Multicentre, Randomised, Double-Blind, Controlled Trial With an Optional Long-Term, Open-Label Extension Phase.",1228,placebo,silodosin,plac_stnd,FALSE
NCT00090103,Phase 3,3,Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment,"A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia",4844,NA,tamsulosin,plac_stnd,FALSE
NCT00919711,Phase 3,2,Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy,A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy,870,not a drug,denosumab,plac_stnd,FALSE
NCT00105300,Phase 3,NA,Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab",300,NA,adalimumab,poss_plac_stnd,NA
NCT00152490,Phase 3,NA,"A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)","A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease",604,NA,certolizumab pegol,poss_plac_stnd,NA
NCT00299546,Phase 3,3,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)",461,NA,golimumab,plac_stnd,TRUE
NCT00152425,Phase 3,NA,"Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).","A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870",392,NA,certolizumab pegol,poss_plac_stnd,NA
NCT00410410,Phase 3,3,A Study of Abatacept in Patients With Active Ulcerative Colitis,"A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy",591,placebo,abatacept,plac_stnd,FALSE
NCT01606761,Phase 3,3,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy",878,placebo,sirukumab,plac_stnd,TRUE
NCT01458574,Phase 3,3,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis",593,placebo,tofacitinib,plac_stnd,FALSE
NCT01860976,Phase 3,2,Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis,A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis,489,placebo,abatacept,plac_stnd,FALSE
NCT01369355,Phase 3,6,A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI),"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease",1282,placebo,ustekinumab,plac_stnd,FALSE
NCT02159053,Phase 3,3,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis","A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis",350,placebo,secukinumab,plac_stnd,FALSE
NCT01392326,Phase 3,3,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis",606,placebo,secukinumab,plac_stnd,FALSE
NCT01232569,Phase 3,2,A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis,"A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis",656,placebo,tocilizumab,plac_stnd,FALSE
NCT01989468,Phase 3,3,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,"A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis",414,placebo,secukinumab,plac_stnd,FALSE
NCT01224171,Phase 3,2,Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease,"A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease",416,placebo,vedolizumab,plac_stnd,FALSE
NCT01458951,Phase 3,2,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis","A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.",547,placebo,tofacitinib,plac_stnd,FALSE
NCT00970632,Phase 3,3,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia",511,placebo,tadalafil,plac_stnd,FALSE
NCT00251706,Phase 3,NA,Amiodarone to Prevent Post-Operative Arrhythmias,"Prophylactic Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valve Replacement, or Repair - PAPABEAR",600,NA,amiodarone,poss_plac_stnd,NA
NCT00216619,Phase 3,2,The Prolonged Use of Topiramate for Preventing Migraine Headaches,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention",834,placebo,topiramate,plac_stnd,TRUE
NCT01370005,Phase 3,3,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus",825,NA,empagliflozin,plac_stnd,FALSE
NCT01261325,Phase 3,3,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures",768,placebo,brivaracetam,plac_stnd,FALSE
NCT00464269,Phase 3,4,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures",400,placebo,brivaracetam,plac_stnd,FALSE
NCT00490035,Phase 3,4,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.",399,placebo,brivaracetam,plac_stnd,FALSE
NCT00740623,Phase 3,3,"A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.",547,placebo,carisbamate,plac_stnd,FALSE
NCT01262677,Phase 3,3,Once-A-Day Pregabalin For Partial Seizures,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures - Protocol A0081194",334,placebo,pregabalin,plac_stnd,FALSE
NCT00318422,Phase 3,NA,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.,1041,glimepiride|rosiglitazone,liraglutide,undefined,NA
NCT00410384,Phase 3,3,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)",819,placebo,belimumab,plac_stnd,TRUE
NCT00782210,Phase 3,3,12 / 48 Week Pivotal PFT vs PBO in COPD I,"Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",625,placebo,olodaterol,plac_stnd,FALSE
NCT00793624,Phase 3,4,Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I,"A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",906,placebo,olodaterol,plac_stnd,FALSE
NCT01425359,Phase 4,2,Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina,"A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus",949,NA,ranolazine,plac_stnd,FALSE
NCT01156571,Phase 3,2,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX),11145,not a drug,cangrelor,plac_stnd,FALSE
NCT00399724,Phase 4,NA,A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus,"A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus.",7376,NA,insulin glargine,poss_plac_stnd,NA
NCT00813995,Phase 3,2,A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074),"A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy",395,placebo,sitagliptin,plac_stnd,FALSE
NCT01590771,Phase 3,2,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy, Alone or in Combination With Metformin",498,placebo,sitagliptin,plac_stnd,FALSE
NCT00399711,Phase 3,NA,Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes,"Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and Safety",560,rosiglitazone|metformin|metformin,repaglinide,undefined,NA
NCT02104804,Phase 3,2,Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control,"A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin",953,placebo,saxagliptin,plac_stnd,FALSE
NCT01455857,Phase 3,3,A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes",460,placebo,exenatide,plac_stnd,FALSE
NCT00265096,Phase 3,3,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis",407,NA,golimumab,plac_stnd,TRUE
NCT00814307,Phase 3,4,"A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis","Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis",611,placebo,tofacitinib,plac_stnd,FALSE
NCT00152386,Phase 3,NA,A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis,"A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate",950,NA,certolizumab pegol,poss_plac_stnd,NA
NCT01519791,Phase 3,2,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis",880,placebo,certolizumab pegol,plac_stnd,FALSE
NCT01721057,Phase 3,3,A Study in Moderate to Severe Rheumatoid Arthritis Participants,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis",684,placebo,baricitinib,plac_stnd,FALSE
NCT00087529,Phase 2/Phase 3,2,A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis,"A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis",439,placebo,rituximab,plac_stnd,FALSE
NCT01212770,Phase 3,4,PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis and a Qualifying Psoriasis Lesion",505,placebo,apremilast,plac_stnd,FALSE
NCT01710358,Phase 3,3,A Study in Moderate to Severe Rheumatoid Arthritis,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy",1307,placebo,baricitinib,plac_stnd,FALSE
NCT00090298,Phase 3,NA,Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058),"A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia",2815,rosuvastatin|ezetimibe|ezetimibe,simvastatin,undefined,NA
NCT01763918,Phase 3,4,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia",331,placebo,evolocumab,plac_stnd,FALSE
NCT00287716,Phase 3,3,Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,"A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis",435,placebo,pirfenidone,plac_stnd,FALSE
NCT00368979,Phase 3,2,Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects,"Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (Dutasteride) in Subjects With Benign Prostatic Hyperplasia.",378,placebo,dutasteride,plac_stnd,FALSE
NCT00377637,Phase 3,4,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,"A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.",370,cyclophosphamide,mycophenolate mofetil,diff_class,FALSE
NCT01396395,Phase 4,2,Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina,"A Prospective, Multi-center, Random, Open-label Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina",402,NA,nicorandil,plac_stnd,FALSE
NCT00063687,Phase 2/Phase 3,NA,Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure,"A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure",400,NA,oxypurinol,poss_plac_stnd,NA
NCT00274079,Phase 4,NA,SPIRIVA in Ususal Care,"A Randomised, Double-blind, Parallel Group, 12 Week Study, Comparing the Effect of Once Daily Tiotropium Lactose Capsule With Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD), naïve to Anticholinergic Agents in Addition to Receiving Their Usual COPD Care",395,NA,tiotropium,poss_plac_stnd,NA
NCT00463567,Phase 2/Phase 3,7,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d.) and Open Label Tiotropium (18 µg o.d.) as Active Controls",2059,placebo,tiotropium,plac_stnd,FALSE
NCT00463866,Phase 4,2,Local Phase 4 Pan-European SMART Study,NA,8424,budesonide,formoterol,undefined,NA
NCT00487539,Phase 2/Phase 3,4,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,"A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis",1065,placebo,golimumab,plac_stnd,FALSE
NCT00439647,Phase 3,2,Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis,"A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men",1199,placebo,zoledronic acid,plac_stnd,FALSE
NCT00074542,Phase 3,NA,An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease,"A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease",364,NA,omega-3-triglycerides incl. other esters and acids,poss_plac_stnd,NA
NCT00393991,Phase 3,4,"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma","A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma",475,NA,fluticasone,plac_stnd,FALSE
NCT00385138,Phase 3,2,Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.,"A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).",5364,NA,cangrelor,plac_stnd,FALSE
NCT02347774,Phase 3,3,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-4 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer",641,placebo,glycopyrronium bromide,plac_stnd,FALSE
NCT00328692,Phase 3,2,PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy",932,placebo,rolofylline,plac_stnd,FALSE
NCT02531035,Phase 3,2,A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes",1405,placebo,sotagliflozin,plac_stnd,FALSE
NCT02460978,Phase 3,3,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two",815,placebo,dapagliflozin,plac_stnd,FALSE
NCT02268214,Phase 3,3,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus",833,placebo,dapagliflozin,plac_stnd,FALSE
NCT01590797,Phase 3,2,A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy, Alone or in Combination With Metformin",467,placebo,sitagliptin,plac_stnd,FALSE
NCT00501020,Phase 4,NA,Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin,"A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA When Added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy When Administered to Subjects With Type 2 Diabetes Mellitus",750,NA,rosiglitazone,poss_plac_stnd,NA
NCT00286468,Phase 3,3,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes",500,NA,alogliptin,plac_stnd,FALSE
NCT00313001,Phase 3,NA,Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.,"Effects of NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea",373,exenatide,insulin aspart,undefined,NA
NCT00286494,Phase 3,3,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus",493,NA,alogliptin,plac_stnd,FALSE
NCT00722371,Phase 3,7,MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2),"A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",1615,placebo,pioglitazone,plac_stnd,FALSE
NCT01606007,Phase 3,3,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.",1282,placebo,dapagliflozin,plac_stnd,FALSE
NCT01392677,Phase 3,2,Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea,"A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea",311,placebo,dapagliflozin,plac_stnd,FALSE
NCT01106677,Phase 3,4,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),"A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy",1284,placebo,canagliflozin,plac_stnd,TRUE
NCT00279201,Phase 4,6,The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV),The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control,2091,NA,insulin lispro,plac_stnd,FALSE
NCT01617434,Phase 3,2,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,451,placebo,liraglutide,plac_stnd,FALSE
NCT02036515,Phase 3,3,Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin",464,NA,ertugliflozin,plac_stnd,FALSE
NCT02414958,Phase 3,3,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),"A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)",730,placebo,empagliflozin,plac_stnd,FALSE
NCT01850615,Phase 3,2,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",323,NA,insulin aspart,plac_stnd,FALSE
NCT02791490,Phase 3,2,A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared With Metformin Up-titration Alone in Subjects With Type 2 Diabetes Mellitus",458,placebo,sitagliptin,plac_stnd,FALSE
NCT00885352,Phase 3,2,Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128),"A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and Pioglitazone",313,placebo,sitagliptin,plac_stnd,FALSE
NCT01472185,Phase 3,2,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus",465,NA,ranolazine,plac_stnd,FALSE
NCT00147758,Phase 3,NA,WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents",400,NA,colesevelam,poss_plac_stnd,NA
NCT00395512,Phase 3,4,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,"A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes",655,placebo,alogliptin,plac_stnd,FALSE
NCT01233622,Phase 3,2,Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride,"A Multi-center, Randomized, Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin 50 mg Bid as add-on Therapy to Metformin Plus Glimepiride in Patients With Type 2 Diabetes",317,placebo,vildagliptin,plac_stnd,FALSE
NCT01023581,Phase 3,7,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes",784,NA,alogliptin,plac_stnd,FALSE
NCT01177813,Phase 3,5,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,"A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise",986,NA,empagliflozin,plac_stnd,FALSE
NCT01175811,Phase 4,2,A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus,A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin,402,NA,insulin glargine,plac_stnd,FALSE
NCT01809327,Phase 3,5,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",1186,NA,canagliflozin,plac_stnd,FALSE
NCT00147719,Phase 3,NA,WelChol® With Metformin in Treating Patients With Type 2 Diabetes,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents",300,NA,colesevelam,poss_plac_stnd,NA
NCT02738879,Phase 3,2,Randomized Sitagliptin Withdrawal Study (MK-0431-845),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus",746,placebo,sitagliptin,plac_stnd,FALSE
NCT02421510,Phase 3,3,"Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy",782,placebo,sotagliflozin,plac_stnd,FALSE
NCT01175824,Phase 4,2,Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies,Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone,478,NA,insulin glargine,plac_stnd,FALSE
NCT00092560,Phase 3,NA,Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036),Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia,587,ezetimibe|ezetimibe,fenofibric acid,undefined,NA
NCT00047424,Phase 3,NA,Stop Atherosclerosis in Native Diabetics Study (SANDS),Stop Atherosclerosis in Native Diabetics Study (SANDS),NA,ace inhibitors,simvastatin,undefined,NA
NCT00327418,Phase 4,NA,CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events,A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS),2800,NA,atorvastatin,poss_plac_stnd,NA
NCT00092157,Phase 3,NA,Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224),"A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patients With Combined Hyperlipidemia-Simvastatin and Fenofibrate Efficacy Trial (SAFARI)",571,simvastatin|simvastatin,simvastatin,undefined,NA
NCT00462748,Phase 3,3,A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121),"A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C <2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/l",786,NA,simvastatin,plac_stnd,FALSE
NCT02739984,Phase 3,2,A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia",424,placebo,evolocumab,plac_stnd,FALSE
NCT00092599,Phase 3,NA,Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.",410,ezetimibe|ezetimibe|placebo,ezetimibe,undefined,NA
NCT00110435,Phase 3,NA,A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077),"A Multicenter, Randomized, Double-blind, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypercholesterolemia",1229,ezetimibe|ezetimibe|atorvastatin,simvastatin,undefined,NA
NCT00440050,Phase 3,2,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease,402,placebo,omega-3-triglycerides incl. other esters and acids,plac_stnd,FALSE
NCT00900146,Phase 2/Phase 3,5,"Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients","Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study",556,placebo,canakinumab,plac_stnd,FALSE
NCT01350804,Phase 3,4,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2309) and A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2309E1)",551,NA,abatacept,plac_stnd,FALSE
NCT00299104,Phase 3,3,A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis,"A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis",755,placebo,rituximab,plac_stnd,FALSE
NCT00634309,Phase 3,2,Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added),Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function,597,placebo,candesartan,plac_stnd,FALSE
NCT01335464,Phase 3,2,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients,"A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)",515,placebo,nintedanib,plac_stnd,FALSE
NCT00391443,Phase 3,2,BUILD 3: Bosentan Use in Interstitial Lung Disease,"Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.",616,placebo,bosentan,plac_stnd,FALSE
NCT01086384,Phase 3,2,Asthma Exacerbation Study,"A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma",2020,NA,vilanterol,plac_stnd,FALSE
NCT02276222,Phase 3,2,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)",1087,glycopyrronium bromide,tiotropium,same_5,FALSE
NCT00102440,Phase 3,3,Febuxostat Versus Allopurinol Control Trial in Subjects With Gout,"A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout",760,febuxostat,allopurinol,same_5,FALSE
NCT00430248,Phase 3,3,Efficacy and Safety of Oral Febuxostat in Participants With Gout,"A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.",2269,febuxostat,allopurinol,same_5,FALSE
NCT01159600,Phase 3,4,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,"A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea",1504,NA,empagliflozin,plac_stnd,FALSE
NCT01512979,Phase 4,2,"Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes","A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patients",316,NA,metformin,plac_stnd,FALSE
NCT00591773,Phase 3,3,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension",551,NA,azilsartan,plac_stnd,FALSE
NCT00099918,Phase 3,NA,Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes,717,NA,vildagliptin,poss_plac_stnd,NA
NCT00321984,Phase 3,3,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD),947,placebo,dexlansoprazole,plac_stnd,FALSE
NCT00143221,Phase 4,NA,Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH),"A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States",350,placebo,sildenafil,poss_plac_stnd,NA
NCT00286442,Phase 3,3,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes",527,NA,alogliptin,plac_stnd,FALSE
NCT00286429,Phase 3,3,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes",390,NA,alogliptin,plac_stnd,FALSE
NCT00154219,Phase 3,NA,Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis,"A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control",1200,NA,lumiracoxib,poss_plac_stnd,NA
NCT00318461,Phase 3,5,To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together,Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes,1091,NA,liraglutide,plac_stnd,FALSE
NCT00622284,Phase 3,2,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,"A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy",1560,not a drug,linagliptin,plac_stnd,TRUE
NCT01798706,Phase 3,2,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,"A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen",350,placebo,lixisenatide,plac_stnd,FALSE
NCT00102765,Phase 4,NA,Study Of Asthma In Patients Of African Descent,"A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone",479,fluticasone|fluticasone,salmeterol,undefined,NA
NCT00764725,Phase 4,2,Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT),"A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX",487,standard care,methotrexate,plac_stnd,TRUE
NCT00353912,Phase 3,NA,Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension,"A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension",571,amlodipine,valsartan,undefined,NA
NCT00993109,Phase 4,2,Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension,"Randomized,Open-label,Parallel Design Comparator Study of Effect of Nifedipine GITS/OROS (Adalat) 30 mg in Combination With Valsartan (Diovan) 80 mg Compared to Valsartan (Diovan) 160 mg Monotherapy in Patients Whose Blood Pressure is Not Well Controlled by Valsartan 80 mg Alone",360,valsartan,nifedipine,diff_class,FALSE
NCT00425997,Phase 4,NA,Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension,"A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hypertension",480,hydrochlorothiazide|hydrochlorothiazide|amlodipine,valsartan,undefined,NA
NCT00000530,Phase 3,NA,Raynaud's Treatment Study (RTS),NA,NA,NA,nifedipine,poss_plac_stnd,NA
NCT00273299,Phase 3,NA,Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension,A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension,607,hydrochlorothiazide,valsartan,undefined,NA
NCT01329029,Phase 4,2,Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS),"Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial",1945,placebo,roflumilast,plac_stnd,FALSE
NCT00174759,Phase 3,NA,CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease,"A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.",1460,NA,clopidogrel,poss_plac_stnd,NA
NCT00413049,Phase 3,2,Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension,"A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Monotherapy",698,NA,valsartan,plac_stnd,TRUE
NCT00386100,Phase 4,2,A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin,"A Randomized, Parallel Group, Double-blind, Multi-center Study Comparing the Efficacy and Safety of AVANDAMET and Metformin After 80 Weeks of Treatment.",688,NA,rosiglitazone,plac_stnd,TRUE
NCT01444430,Phase 3,2,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,"A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma",12460,NA,formoterol,plac_stnd,FALSE
NCT00679380,Phase 3,4,(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,"Efficacy and Safety of Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablets in Patients With Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Double-Dummy, Comparative Study Versus Placebo With an Additional Reference Arm Evaluating Entocort®EC",514,placebo,budesonide,plac_stnd,FALSE
NCT00680953,Phase 3,3,Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis,"A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)",1262,placebo,denosumab,plac_stnd,FALSE
NCT02099110,Phase 3,5,"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy",1233,NA,ertugliflozin,plac_stnd,FALSE
NCT00235014,Phase 4,4,A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT),A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT),1204,placebo,trandolapril,plac_stnd,FALSE
NCT00375388,Phase 3,NA,"The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial",Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial,400,NA,metformin,poss_plac_stnd,NA
NCT02033889,Phase 3,3,A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.",621,NA,ertugliflozin,plac_stnd,FALSE
NCT00091793,Phase 3,2,Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis,"A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis",332,placebo,denosumab,plac_stnd,FALSE
NCT00403910,Phase 3,NA,Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study,Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure,500,NA,canrenone,poss_plac_stnd,NA
NCT03021343,Phase 3,2,Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients,Effect of ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial,360,standard care,colchicine,plac_stnd,FALSE
NCT00290927,Phase 3,NA,Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus,"Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents (OHA); OHA Therapy Controlled, Open, Randomized, Parallel Group, Comparative (Superiority), 16-week, Multinational, Multicenter Study",390,NA,insulin glulisine,poss_plac_stnd,NA
NCT00439738,Phase 4,2,Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults,"A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients",412,amlodipine,valsartan,diff_class,FALSE
NCT01365455,Phase 3,5,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,"A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",738,NA,secukinumab,plac_stnd,FALSE
NCT01177384,Phase 3,2,Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130),"A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Acarbose Monotherapy",380,placebo,sitagliptin,plac_stnd,FALSE
NCT01009580,Phase 3,2,Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes,"A 26-week, Randomised, Open-labelled, Two-arm, Parallel-group, Treat-to-target Trial Comparing Efficacy and Safety of Soluble Insulin Analogue Combination (SIAC) Twice Daily (BID) With Biphasic Insulin Aspart (BIAsp) 30 BID, With or Without Metformin, With or Without DPP-4 Inhibitor, With or Without Pioglitazone in Subjects With Type 2 Diabetes in Inadequate Glycaemic Control on Once or Twice Daily Premixed or Self-mixed Insulin Regimen With or Without OADs (BOOST™: Intensify Premix 1)",447,NA,insulin degludec,plac_stnd,FALSE
NCT01059812,Phase 3,2,A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes,A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL),424,NA,insulin degludec,plac_stnd,FALSE
NCT01228747,Phase 3,2,"A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)","A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged ≥16 Years, With Generalized Tonic-clonic (GTC) Seizures",361,placebo,levetiracetam,plac_stnd,FALSE
NCT01336023,Phase 3,3,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension",1663,NA,insulin degludec,plac_stnd,FALSE
NCT00570739,Phase 3,4,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.","Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes",502,placebo,colesevelam,plac_stnd,FALSE
NCT00856544,Phase 3,4,"A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications","Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS",795,placebo,tofacitinib,plac_stnd,FALSE
NCT01578850,Phase 4,2,Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening,"A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s)",491,placebo,etanercept,plac_stnd,FALSE
NCT00333151,Phase 3,NA,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes,576,rosiglitazone|metformin,liraglutide,undefined,NA
NCT00696384,Phase 3,3,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,"An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension",418,placebo,azilsartan,plac_stnd,FALSE
NCT00099905,Phase 3,NA,A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes,A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes,639,NA,vildagliptin,poss_plac_stnd,NA
NCT00099944,Phase 3,3,Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes,Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes,515,placebo,vildagliptin,plac_stnd,FALSE
NCT00219154,Phase 3,NA,A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine,"A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension",1125,NA,aliskiren,poss_plac_stnd,NA
NCT00171002,Phase 3,NA,Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone,A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy,936,amlodipine,valsartan,undefined,NA
NCT01031680,Phase 3,2,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension","A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care",922,placebo,dapagliflozin,plac_stnd,FALSE
NCT00454662,Phase 4,2,Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study),Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study),5141,"C03A LOW-CEILING DIURETICS, THIAZIDES",azelnidipine,diff_class,TRUE
NCT00698646,Phase 4,3,Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.,"A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very Elderly Patients With Essential Hypertension",384,NA,valsartan,plac_stnd,FALSE
NCT00734474,Phase 2/Phase 3,9,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,"A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin",1202,NA,dulaglutide,plac_stnd,FALSE
NCT00365170,Phase 4,NA,Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes,"A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes",419,insulin,insulin aspart,undefined,NA
NCT01392573,Phase 3,2,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,"A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes",413,NA,liraglutide,plac_stnd,FALSE
NCT00963599,Phase 3,4,Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117),"A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Fall Study",907,NA,montelukast,plac_stnd,FALSE
NCT00712673,Phase 3,4,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin",680,placebo,lixisenatide,plac_stnd,FALSE
NCT01674647,Phase 3,2,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,"A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion",1504,vitamin k,rivaroxaban,diff_class,FALSE
NCT00321737,Phase 3,3,Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis,A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.,445,placebo,dexlansoprazole,plac_stnd,FALSE
NCT01474369,Phase 3,3,Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease,"A Phase 3, Randomized, Double Blind, Placebo Control, Multicenter Study to Evaluate the Efficacy and Safety of TAK- 438 (10 and 20 mg Once-Daily) in Patients With Non-Erosive Gastroesophageal Reflux Disease.",827,placebo,vonoprazan fumarate,plac_stnd,FALSE
NCT00092768,Phase 3,NA,A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED),"A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)",500,etoricoxib|celecoxib,etoricoxib,undefined,NA
NCT01292473,Phase 3,4,"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)",323,NA,omalizumab,plac_stnd,TRUE
NCT01646320,Phase 3,2,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin",320,placebo,dapagliflozin,plac_stnd,FALSE
NCT01709110,Phase 4,2,VERtebral Fracture Treatment Comparisons in Osteoporotic Women,Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures,1366,teriparatide,risedronate,diff_class,FALSE
NCT00783237,Phase 4,2,Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431),Onset of Action of Mometasone Furoate Nasal Spray vs. Placebo in Induced Allergic Rhinitis,340,placebo,mometasone,plac_stnd,FALSE
NCT01316900,Phase 3,4,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,A Multicenter Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GW642444 and With Tiotropium Over 24 Weeks in Subjects With COPD,846,NA,vilanterol,plac_stnd,FALSE
NCT00036439,Phase 3,NA,A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis,"A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis",364,NA,infliximab,poss_plac_stnd,NA
NCT00100620,Phase 3,NA,Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis,Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis,802,NA,zoledronic acid,poss_plac_stnd,NA
NCT01882439,Phase 3,4,Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor",395,placebo,tofacitinib,plac_stnd,TRUE
NCT00387088,Phase 3,2,Tiotropium / Respimat One Year Study in COPD.,"Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD",3991,not a drug,tiotropium,plac_stnd,FALSE
